Prime Medicine unveils program for treatment of AATD

Prime Medicine (PRME) unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency, AATD, the next program within its liver franchise. Prime Medicine expects to file an investigational new drug and/or clinical trial application in mid-2026. “We are excited to announce our AATD program, the second high-value program to emerge from our liver franchise, and the second liver program that we expect to advance into the clinic next year,” said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. “This program exemplifies our strategy of using our proprietary, modular liver LNP to accelerate the development of new Prime Editors, as well as our ability to leverage learnings, regulatory frameworks and manufacturing synergies to efficiently advance our efforts. We look forward to progressing our AATD and Wilson’s Disease programs toward clinical data in 2027, where we hope to demonstrate Prime Editing’s best-in-class potential across two of the largest genetic liver diseases.”